Recently, it has been shown that suppression of RIPK1 kinase activity improves anti-tumor immunity by modulating tumor-associated macrophages26; this occurs independently of RIPK3-mediated necroptosis, demonstrating that the kinase activity of RIPK1 can be viewed as a new immunomodulatory target for the development of new anti-cancer therapies. The gene discussed is RIPK1; the disease is cancer.